A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer
This is a study using pembrolizumab (MK-3475, KEYTRUDA®) for first-line treatment of
participants with advanced/unresectable (inoperable) or metastatic urothelial cancer who are
ineligible for cisplatin-based therapy. The primary study objective is to determine the
objective response rate (ORR) in all participants, in participants whose tumours rely on
programmed cell death ligand 1 (PD-L1) protein (PD-L1-positive tumours), and in participants
with strongly PD-L1-positive tumours.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society